Skip to content

Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device

Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02445313
Enrollment
100
Registered
2015-05-15
Start date
2015-06-30
Completion date
2019-02-12
Last updated
2019-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related Macular Degeneration (AMD)

Brief summary

The investigators would like to know if different imaging devices can improve the quality of images and visualization of imaged tissues. Also, the investigators would like to find out whether these changes are useful in the diagnosis and treatment of eye diseases. Using images of previous participants will allow us to demonstrate the advancement of different technologies, as well be used to allow comparisons between current technologies.

Detailed description

To test the quality of images from the Nidek MP-3 device and to measure Geographic Atrophy (GA) in patients with Age-related Macular Degeneration (AMD).

Interventions

DEVICENidek MP-3

Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD

Sponsors

Doheny Image Reading Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Normal, healthy participants and patients with AMD

Exclusion criteria

1. Those suffering from head, neck or other injury which makes them unable to position themselves in head restraint for imaging 2. Participants who are unable to maintain retinal fixation on a specified target 3. Participants unable to achieve sufficient pupil dilation and alignment stability for imaging to take place 4. Patients with media opacity which preclude high quality imaging will be excluded. 5.

Design outcomes

Primary

MeasureTime frame
Geographic Atrophy1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026